The explosive rise of GLP-1 medications for diabetes and weight management has created a high-stakes challenge for HR leaders. Demand from employees is surging, but costs are straining benefits budgets, and questions remain around long-term outcomes, equity, and access. Employers must make tough decisions about coverage, plan design, and communication while maintaining trust and supporting workforce wellbeing.
This Session Will Examine:
- The financial strain GLP-1s place on benefits budgets as adoption surges.
- Balancing clinical value, employee demand, and long-term affordability.
- Plan design, eligibility, and access as critical levers of fairness.
- The importance of clear communication to sustain employee trust.
- Measuring wellness, productivity, and cultural impact—not just pharmacy spend.
